Day: June 7, 2022

         Global Bioenergies receives first orders from a number of major cosmetics players totalling several tonnes of Isonaturane®12 Paris, 07 June 2022 – Less than two months after the commissioning of the Pomacle commercial production unit, Global Bioenergies has received its first orders totalling several tonnes of Isonaturane®12 from a number of major cosmetics players, including L’Oréal. Isonaturane® 12 is the trademark registered by Global Bioenergies to designate its naturally sourced isododecane product. Isododecane is one of the most important molecules used in the cosmetics industry, both in the make-up segment, where it is the only molecule able to deliver longwear properties, and in skincare and haircare, where it endows textures with lightness and softness. Thanks to Global Bioenergies, this compound is now available in a...

Kinohold (Bis) SA announces private sale of 180,001 shares to Eddy Duquenne (CEO of Kinepolis) and members of the Bert family Inside information – Regulatory release 7 June 2022, 7 a.m. Kinepolis Group NV has been informed that Kinohold (Bis) SA, the investment vehicle ultimately economically owned1 by four members of the Bert family2, has transferred, by means of a private sale, 180,001 existing common Kinepolis shares or c. 0.66% of the current outstanding share capital. Kinepolis has not received any proceeds from this private placement. Kinohold has sold the shares at the request of Geert and Koenraad Bert. In order to reaffirm their belief in the future and growth strategy of Kinepolis and ensure a stable shareholding, Eddy Duquenne, Kinepolis’ CEO, has acquired 100,000 of the shares and 80,001 of the shares have been reallocated...

New multi-year contract from Public Health Agency of Canada to procure IMVAMUNE® smallpox vaccineCOPENHAGEN, Denmark, June 7, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Public Health Agency of Canada (PHAC) will be purchasing IMVAMUNE® smallpox vaccine at a value of approximately USD 56 million. The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA. Deliveries of vaccines under this five-year contract are expected to occur from 2023. Hence this contract will have no impact on the Company’s financial guidance for 2022. In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak and to explore opportunities...

Designed to help clinicians overcome catheter identification confusion WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region. The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety. The new, 20cm Arrow Pressure Injectable Midline with brightly colored yellow hubs and labeling, will help clinicians overcome catheter identification confusion, which can lead to infusion mistakes that can harm patients. Additional features include:Available in 1-lumen and 2-lumen configurations TAPERFREE design, which assures consistent...

YERINGTON, Nev., June 06, 2022 (GLOBE NEWSWIRE) — Nevada Copper (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) provides an update on recent operational events that occurred at its Pumpkin Hollow underground copper mine located in Yerington, Nevada (the “Underground Mine”) and on its financial liquidity. Restricted Access to East South Stopes The Underground Mine encountered operational and geotechnical challenges in the latter part of May that are expected to delay stope mining in the East South mining area and result in reduced concentrate production for the second quarter of 2022.  Access to planned stopes for the months of June and July have been delayed due to an unidentified weak rock structure being encountered in the main ramp to the East South Zone that requires additional drilling and geotechnical...

WESTLAKE, Texas, June 06, 2022 (GLOBE NEWSWIRE) — Goosehead Insurance, Inc. (“Goosehead” or the “Company”) (NASDAQ: GSHD), a rapidly growing independent personal lines insurance agency, announced today that Mark E. Jones, Chairman and CEO will present at the 42nd Annual William Blair Growth Stock Conference on Tuesday June 7th at 3:20 PM Central Time. Joining Mr. Jones at the conference will be Mark Colby, Chief Financial Officer; Brian Pattillo, VP Strategy; and Dan Farrell, VP Capital Markets. A link to the live webcast of the presentation will be available in the investor relations section of the Company’s website at ir.gooseheadinsurance.com. A replay of the presentation will be accessible on the website via the same link following the conference. About Goosehead Goosehead (NASDAQ: GSHD) is a rapidly growing and innovative...

FREMONT, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced that President and CEO Gayn Erickson will participate in a fireside chat at the JP Morgan Chase Silicon Carbide (SiC) & Gallium Nitride (GaN) Week today, Tuesday, June 7, at 10:00 a.m. Eastern time (7:00 a.m. PT). You may register to view the presentation here. “We continue to be excited about the silicon carbide market for electric vehicles and electrification of the worldwide infrastructure, as well as gallium nitride that is used in both consumer applications and for photovoltaic and automotive applications,” said Mr. Erickson. “I look forward to discussing our semiconductor wafer level and singulated die test and burn-in solutions and the...

MARIETTA, GA, June 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire  – Global Consumer Acquisition Corp. (NASDAQ: GACQU, GACQ, GACQW) (“GACQ” or the “Company”), a special purpose acquisition company, announced today that, on June 6, 2022, it notified the trustee of the Company’s trust account of its intent to extend the time available to the Company to consummate a business combination from June 11, 2022 to September 11, 2022 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under GACQ’s governing documents. In connection with such Extension, Global Consumer Acquisition LLC, the Company’s sponsor, will deposit an aggregate of $1,826,300 into GACQ’s trust account prior to June 11, 2022, on behalf of the Company. GACQ will issue a press release the day after the applicable deadline announcing...

–Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors –Toripalimab continues to demonstrate synergy as the cornerstone in innovative combination therapies SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company highlighted its pipeline advances in immunotherapy drugs, including anti-PD-1 monoclonal antibody toripalimab and anti-BTLA monoclonal antibody icatolimab (TAB004/JS004), through nearly 40 data presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,...